taurine has been researched along with Depressive Disorder, Major in 7 studies
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
Excerpt | Relevance | Reference |
---|---|---|
"Taurine is an important amino acid required for brain development." | 5.91 | Taurine Alleviates Chronic Social Defeat Stress-Induced Depression by Protecting Cortical Neurons from Dendritic Spine Loss. ( Cai, G; Fan, Z; Han, J; Li, X; Li, Y; Luo, D; Wang, R; Wu, S; Zhang, H; Zhang, L; Zhu, Y; Zhuo, L, 2023) |
"Taurine is an important amino acid required for brain development." | 1.91 | Taurine Alleviates Chronic Social Defeat Stress-Induced Depression by Protecting Cortical Neurons from Dendritic Spine Loss. ( Cai, G; Fan, Z; Han, J; Li, X; Li, Y; Luo, D; Wang, R; Wu, S; Zhang, H; Zhang, L; Zhu, Y; Zhuo, L, 2023) |
"Taurine transporter was present in 16% of CD4+ and CD8+ lymphocytes in controls and patients." | 1.33 | Taurine transport and transporter localization in peripheral blood lymphocytes of controls and major depression patients. ( Fazzino, F; Lima, L; Mata, S; Urbina, M, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Zhu, Y | 1 |
Wang, R | 1 |
Fan, Z | 1 |
Luo, D | 1 |
Cai, G | 1 |
Li, X | 1 |
Han, J | 1 |
Zhuo, L | 1 |
Zhang, L | 1 |
Zhang, H | 1 |
Li, Y | 1 |
Wu, S | 1 |
Helton, SG | 1 |
Lohoff, FW | 1 |
Raj, YP | 1 |
Witte, J | 1 |
Bentley, K | 1 |
Evins, AE | 1 |
Clain, AJ | 1 |
Baer, L | 1 |
Pedrelli, P | 1 |
Fava, M | 1 |
Mischoulon, D | 1 |
Sher, L | 1 |
Fazzino, F | 1 |
Urbina, M | 1 |
Mata, S | 1 |
Lima, L | 1 |
Maes, M | 1 |
Verkerk, R | 1 |
Vandoolaeghe, E | 1 |
Lin, A | 1 |
Scharpé, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence[NCT00452543] | Phase 4 | 23 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Scores on the HAM-D-17 typically fall into the following ranges: a) Not depressed: 0-7; b) Mildly depressed: 7-15; c) Moderately depressed: 15-25; d) Severely depressed: over 25. A decrease of 50% or more in the Hamilton-D score is considered to be a positive response to treatment, while a score of 7 or less is considered typical of remission. We measure the change in total score from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From baseline visit to Week 12 (or early discontinuation visit)
Intervention | Scores on a scale (Mean) |
---|---|
Escitalopram Plus Acamprosate | -5.6 |
Escitalopram Plus Placebo | -7.8 |
The TLFB assesses recent drinking behavior. On the TLFB, clients retrospectively estimate their daily alcohol consumption in standard drinks over a time period ranging from 7 days to 24 months prior to the interview, and thus the measure provides quantitative estimates of alcohol use. One standard drink on the TLFB was defined as: 12 oz beer (5% alcohol by volume), 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
Intervention | Drinking days (Mean) |
---|---|
Escitalopram Plus Acamprosate | 61 |
Escitalopram Plus Placebo | 61 |
Total Drinks Consumed per Drinking Day on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
Intervention | Drinks consumed per drinking day (Mean) |
---|---|
Escitalopram Plus Acamprosate | 4 |
Escitalopram Plus Placebo | 4 |
Total Drinks Consumed per Week on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
Intervention | Drinks consumed per week (Mean) |
---|---|
Escitalopram Plus Acamprosate | 15 |
Escitalopram Plus Placebo | 15 |
2 reviews available for taurine and Depressive Disorder, Major
Article | Year |
---|---|
Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Anxiety Disorders; Comorbidity; Depressi | 2015 |
Alcoholism and suicidal behavior: a clinical overview.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Tricyclic; Anxiety; Comorbidity; | 2006 |
2 trials available for taurine and Depressive Disorder, Major
Article | Year |
---|---|
A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder.
Topics: Acamprosate; Adult; Alcoholism; Citalopram; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry) | 2012 |
Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.
Topics: Adult; Aged; Alanine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine; Asparagine; | 1998 |
3 other studies available for taurine and Depressive Disorder, Major
Article | Year |
---|---|
Taurine Alleviates Chronic Social Defeat Stress-Induced Depression by Protecting Cortical Neurons from Dendritic Spine Loss.
Topics: Amino Acids; Animals; Dendritic Spines; Depression; Depressive Disorder, Major; Mice; Mice, Inbred C | 2023 |
Gambling on acamprosate: a case report.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents, Second-Generation; Comorbidity; | 2010 |
Taurine transport and transporter localization in peripheral blood lymphocytes of controls and major depression patients.
Topics: Adolescent; Adult; Depressive Disorder, Major; Humans; Lymphocytes; Membrane Glycoproteins; Membrane | 2006 |